Free IGF-1, Intact IGFBP-4, and PicoPAPP-A are Altered in Acute Myocardial Infarction Compared to Stable Coronary Artery Disease and Healthy Controls.


Journal

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
ISSN: 1439-4286
Titre abrégé: Horm Metab Res
Pays: Germany
ID NLM: 0177722

Informations de publication

Date de publication:
Feb 2019
Historique:
pubmed: 30 11 2018
medline: 30 5 2019
entrez: 30 11 2018
Statut: ppublish

Résumé

Insulin-like growth factor-1 (IGF-1) and its binding proteins have been implicated in the pathophysiology of coronary artery disease (CAD) and myocardial infarction (MI). We investigated components of the IGF-1 system in circulation at the time of acute MI and following reperfusion in relation to levels of stable CAD patients and controls. Patients with MI (MI Group, n=31) treated with percutaneous coronary intervention (PCI) were compared to patients with stable CAD subjected to scheduled PCI (CAD Group, n=40) and controls with symptoms mimicking CAD without stenosis in angiography (Control Group, n=43). The number and extent of stenosis were recorded. Total and free IGF-1, total and intact IGF binding protein (IGFBP)-3 and -4, pico-Pregnancy Associated Plasma Protein-A (PAPP-A), and the known markers ALT, AST, CK and CK-MB were measured at baseline and 6 or 24 h after the intervention. Patients with MI had higher free IGF-1 (p=0.003) and PAPP-A (p=0.011), but lower intact IGFBP-4 (p=0.006) compared with patients with stable CAD or healthy controls. None of the investigated molecules changed following reperfusion or correlated with the extent of stenosis. AST (p<0.001), CK (p<0.001) and CK-MB (p<0.001), were also higher. Free IGF-1, intact IGFBP-4 and PAPP-A could predict MI, but with lower accuracy than CK-MB. In conclusion, free IGF-1 levels are higher in MI compared to CAD patients and controls and this could result from increased cleavage of its binding protein IGFBP-4 by the higher PAPP-A levels. Free IGF-1, intact IGFBP-4, and/or PAPP-A are inferior to CK-MB as predictors or markers of myocardial damage.

Identifiants

pubmed: 30497090
doi: 10.1055/a-0794-6163
doi:

Substances chimiques

Biomarkers 0
Insulin-Like Growth Factor Binding Protein 4 0
Insulin-Like Growth Factor I 67763-96-6
Pregnancy-Associated Plasma Protein-A EC 3.4.24.-

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

112-119

Informations de copyright

© Georg Thieme Verlag KG Stuttgart · New York.

Déclaration de conflit d'intérêts

CSM is a consultant of Ansh Laboratories. ADA, DK, JU, SAP, EP, NP, NK and FE have nothing to declare in respect to this study.

Auteurs

Athanasios D Anastasilakis (AD)

Department of Endocrinology, 424 General Military Hospital, Thessaloniki, Greece.

Dimitrios Koulaxis (D)

Department of Cardiology, 424 General Military Hospital, Thessaloniki, Greece.

Jagriti Upadhyay (J)

Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Section of Endocrinology, Boston VA Healthcare System, Harvard Medical School, Boston, MA, USA.

Eirini Pagkalidou (E)

Department of Hygiene and Epidemiology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Nikoleta Kefala (N)

Department of Cardiology, 424 General Military Hospital, Thessaloniki, Greece.

Nikolaos Perakakis (N)

Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Stergios A Polyzos (SA)

First Department of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Fotios Economou (F)

Department of Cardiology, 424 General Military Hospital, Thessaloniki, Greece.

Christos S Mantzoros (CS)

Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH